- Home
- PAVM vs KZIA Comparison
PAVM vs KZIA Comparison
Compare PAVM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | KZIA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 161.5M |
| IPO Year | 2016 | 1999 |
Fundamental Metrics
Financial Performance| Metric | PAVM | KZIA |
|---|---|---|
| Price | $7.15 | $6.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $510.00 | $17.67 |
| AVG Volume (30 Days) | 21.4K | ★ 245.6K |
| Earning Date | 11-13-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $29,000.00 | ★ $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $450.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.00 | $2.86 |
| 52 Week High | $26.85 | $17.40 |
Technical Indicators
Market Signals| Indicator | PAVM | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 92.38 | 40.47 |
| Support Level | $0.21 | $5.44 |
| Resistance Level | $9.26 | $6.96 |
| Average True Range (ATR) | 0.36 | 1.44 |
| MACD | 0.81 | -0.51 |
| Stochastic Oscillator | 74.74 | 16.09 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.